Experimental HIV vaccine shows promise in early safety trial

NCT ID NCT05781542

Completed ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 1 trial tested a DNA vaccine designed to teach the immune system to recognize HIV. 46 healthy adults received the vaccine with or without a protein boost. The main goal was to see if it is safe and whether it triggers the right immune cells. Results will help decide if further studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DNA vaccine (sD-NP-GT8) plus IL-12, with or without an HIV protein boost (Trimer 4571) and an adjuvant (3M-052-AF)
What this could lead to: If successful, this could point toward a vaccine that trains the immune system to make special antibodies that block many HIV strains.
What could go wrong: This is an early Phase 1 trial with only 46 healthy volunteers, so it is mainly checking safety and basic immune responses. It is far too early to know if it will actually prevent HIV.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Alabama CRS (Site ID: 31788)

Birmingham, Alabama, 35294, United States
Bridge HIV CRS

San Francisco, California, 94102, United States
Brigham and Women's Hospital Vaccine CRS [30007]

Boston, Massachusetts, 02115, United States
CAPRISA eThekwini CRS

Durban, KwaZulu-Natal, 4013, South Africa
Durban Adult HIV CRS

Durban, KwaZulu-Natal, South Africa
Groote Schuur HIV CRS (Site ID: 31708)

Cape Town, Western Cape, 7925, South Africa
San Francisco Vaccine and Prevention CRS

San Francisco, California, 94102, United States
Soweto HVTN CRS

Johannesburg, Gauteng, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.